0001355790
false
0001355790
2023-09-15
2023-09-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
September 15, 2023
INTERNATIONAL STEM CELL CORPORATION
(Exact name of registrant as specified in its
charter)
Delaware |
000-51891 |
20-4494098 |
(State or other jurisdiction
of incorporation) |
(Commission
File Number) |
(IRS Employer
Identification Number) |
9745 Businesspark Ave, San Diego, California
92131
(Address of principal executive offices, including
zip code)
(760) 940-6383
(Registrant’s telephone number, including
area code)
5950 Priestly Drive, Carlsbad, CA 92008
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b) |
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CAR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
None |
N/A |
N/A |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 |
Entry into a Material Definitive Agreement. |
On September 15, 2023, International Stem Cell Corporation
(the “Company”) and Dr. Andrey Semechkin agreed to extend (until September 15, 2024) the maturity date of the loan (in the
principal amount of $2,900,000) from Dr. Semechkin to the Company that had been reflected in a promissory note dated March 15, 2023 (the
“Original Note”), and which would have been due on September 15, 2023. In exchange for the Original Note, the Company issued
to Dr. Semechkin an unsecured, non-convertible promissory note in the principal amount of $2,900,000 (the “Note”) with the
extended maturity date. Dr. Semechkin is the Company’s Co-Chairman and Chief Executive Officer.
The outstanding principal amount under the Note accrues
interest at a rate of four and a half percent (4.5%) per annum. The Note is due and payable September 15, 2024 but may be pre-paid by
the Company without penalty at any time.
The foregoing summary of the Note is qualified in
its entirety by reference to the full text of the form of Note filed as Exhibit 10.1 to this Current Report on Form 8-K.
Item 2.03 |
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of the Registrant. |
The information disclosed in Item 1.01 is incorporated herein by reference.
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
INTERNATIONAL STEM CELL CORPORATION |
|
|
|
Date: September 18, 2023 |
By: |
|
/s/ Russell Kern |
|
|
|
Russell Kern |
|
|
|
Executive Vice President,
Chief Scientific Officer and
Principal Financial Officer |
Exhibit 10.1
INTERNATIONAL STEM CELL CORPORATION
PROMISSORY NOTE
FOR VALUE RECEIVED, and subject to the terms and
conditions set forth herein, on this 15th day of September, 2023 (the “Issuance Date”), International Stem Cell Corporation,
a Delaware corporation, with offices located at 9745 Businesspark Ave, San Diego, CA (the “Borrower”), hereby unconditionally
promises to pay to the order of Andrey Semechkin or his assigns (the “Noteholder”), the principal amount of two
million and nine hundred thousand U.S. dollars ($2,900,000) (the “Loan”), together with all accrued interest thereon,
as provided in this Promissory Note (the “Note”).
WHEREAS, on March 15, 2023, the Noteholder was
issued a Promissory Note in the principal amount of two million and nine hundred thousand U.S. dollars ($2,900,000) by the Borrower
(the “Original Note”);
WHEREAS, as of the date hereof, the accrued and
unpaid interest on the Original Note was approximately $518,100;
WHEREAS, Borrower and Noteholder wish to extend
the Maturity Date of the Original Note by issuing this Promissory Note in exchange for the Original Note.
1. LOAN TERMS; PREPAYMENT
1.1 Total Outstanding Principal. As of
the date of this Note, the total principal amount outstanding shall equal to two million and nine hundred thousand U.S. dollars ($2,900,000).
1.2 Final Payment Date. The aggregate unpaid
principal amount of the Loan and all accrued and unpaid interest, together with all accrued and unpaid interest payable on the Original
Note and any predecessor notes, shall be due and payable on September 15, 2024 (the “Maturity Date”).
1.3 Optional Prepayment. The Borrower may
prepay the Loan in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid
together with accrued interest thereon to the date of prepayment.
2. INTEREST.
2.1 Interest Rate. The outstanding principal
amount of the Loan made hereunder shall bear interest at the annual rate of four and a half percent (4.5%) from the Issuance Date
of this Note until the Loan is paid in full, whether at maturity, by prepayment or otherwise.
2.2 Interest Payment Dates. Interest shall
be payable on maturity, or earlier with respect to any prepayment.
2.3 Computation of Interest. All computations
of interest shall be made on the basis of a year of 360 days and the actual number of days elapsed. Interest shall begin to accrue on
the Loan on the Issuance Date, and shall not accrue on any portion of the Loan (including all of the Loan if so paid) for the day on which
such portion of the Loan is paid in full, whether at maturity, by prepayment, or otherwise.
2.4 Interest Rate Limitation. If at any
time and for any reason whatsoever, the interest rate payable on the Loan shall exceed the maximum rate of interest permitted to be charged
by the Noteholder to the Borrower under applicable law, such interest rate shall be reduced automatically to the maximum rate of interest
permitted to be charged under applicable law, and that portion of any sum paid attributable to that portion of such interest rate that
exceeds the maximum rate of interest permitted by applicable law shall be deemed a voluntary prepayment of principal.
3. PAYMENT MECHANICS
3.1 All payments of principal and interest shall
be made in lawful money of the United States of America by check or by wire transfer of immediately available funds to the Noteholder’s
account at a bank specified by the Noteholder in writing to the Borrower from time to time.
4. STANDARD PROVISIONS
4.1 Governing Law. This Note and any claim,
controversy, dispute or cause of action based upon, arising out of or relating to this Note, and the transactions contemplated hereby,
shall be governed by the laws of the State of California.
4.2 Counterparts. This Note may be executed
in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
IN WITNESS WHEREOF, the Borrower has executed
this Note as of the Issuance Date written above.
|
|
|
|
|
BORROWER |
|
|
|
NOTEHOLDER |
|
|
|
International Stem Cell Corporation |
|
|
|
Andrey Semechkin |
|
|
|
|
|
|
|
|
|
|
|
Signature |
|
|
|
Signature |
Russell Kern
Executive Vice President,
Chief Scientific Officer and
Principal Financial Officer
v3.23.3
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Jul 2024 to Aug 2024
International Stem Cell (QB) (USOTC:ISCO)
Historical Stock Chart
From Aug 2023 to Aug 2024